Accessibility Menu
Elekta Ab (publ) Stock Quote

Elekta Ab (publ) (OTC: EKTAY)

$5.26
(0.5%)
+0.03
Price as of October 22, 2025, 1:06 p.m. ET

KEY DATA POINTS

Current Price
$5.26
Daily Change
(0.5%) +$0.03
Day's Range
$5.26 - $5.29
Previous Close
$5.23
Open
$5.29
Beta
0.73
Volume
3,524
Average Volume
4,262
Market Cap
1.9B
Market Cap / Employee
$5.23M
52wk Range
$4.36 - $6.54
Revenue
-
Gross Margin
0.37%
Dividend Yield
4.73%
EPS
$0.07
CAPs Rating
-
Industry
Healthcare Equipment and Supplies

The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More

Elekta Ab (publ) Return vs. S&P

1 Year5 Year5 Year AnnualizedSince IPO
EKTAY-16.6%-51.78%-13.57%+167%
S&P+15.06%+95.03%+14.29%+666%

Elekta Ab (publ) Company Info

Elekta AB operates as a medical technology company. It engages in the provision of clinical solutions for the treatment of cancers and brain disorders. The firm's products and solutions include radiotherapy, stereotactic radiosurgery, oncology informatics, brachytheraphy, neurosurgery, and particle therapy. It operates through the following geographical segments: North and South America, Europe, Middle East and Africa and Asia Pacific. The company was founded by Lars Leksell and Laurent Leksell in 1972 and is headquartered in Stockholm, Sweden.

Financial Health

General

Q3 2025YOY Change
Revenue$379.69M5.5%
Gross Profit$139.76M7.2%
Gross Margin36.81%0.6%
Market Cap$1.78B-22.2%
Market Cap / Employee$0.39M0.0%
Employees4.6K-1.8%
Net Income$11.04M65.2%
EBITDA$37.80M-2.7%

Currently no data to display

Revenue Growth Rate

Currently no data to display.

Earnings Per Share Growth Rate

Currently no data to display.

Assets

Q3 2025YOY Change
Net Cash$282.79M28.2%
Accounts Receivable$365.99M0.0%
Inventory310.4-5.6%

Liabilities

Q3 2025YOY Change
Long Term Debt$679.73M24.3%
Short Term Debt$113.22M-35.4%

Ratios

Q3 2025YOY Change
Return On Assets0.84%-2.8%
Return On Invested Capital6.86%-1.1%

Cash Flow

Q3 2025YOY Change
Free Cash Flow-$11.98M77.0%
Operating Free Cash Flow-$8.96M80.7%

Valuation

MetricQ4 2024Q1 2025Q2 2025Q3 2025YoY Change
Price to Earnings23.9523.3395.6776.17237.96%
Price to Book2.282.301.992.03-14.86%
Price to Sales1.361.351.141.09-22.43%
Price to Tangible Book Value-8.88-7.02-6.59-5.53-40.63%
Price to Free Cash Flow TTM21.5219.8213.7110.41-45.59%
Enterprise Value to EBITDA49.8042.7522.6563.67-14.72%
Free Cash Flow Yield4.6%5.0%7.3%9.6%83.80%
Return on Equity10.1%9.9%2.2%2.6%-76.28%
Total Debt$868.22M$801.31M$784.56M$792.95M9.77%

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.